Tethys Bioscience, Inc. and Duke Clinical Research Institute Establish PREVAIL Initiative to Improve Care and Reduce Incidence of Type 2 Diabetes

Published: Mar 30, 2011

EMERYVILLE, Calif.--(BUSINESS WIRE)--Tethys Bioscience, Inc. and Duke Clinical Research Institute (DCRI) have established the PREVAIL patient registry, a multi-center, national initiative that will analyze primary care ambulatory practices for risk factor management of patients at high risk of conversion to type 2 diabetes in the US. Data from PREVAIL (PRovision of EVidence-based Therapies Among IndividuaLs at High Risk for Type 2 Diabetes) will provide insight into the challenges faced in diabetes prevention, and may be used by physicians, quality improvement personnel, healthcare administrators and others to optimize practice algorithms and create targeted educational interventions for high-risk patients with the goal of improving therapeutic outcomes and reducing the incidence of type 2 diabetes and associated cardiovascular disease. The objective of PREVAIL is to improve physician use of evidence-based intervention practices that can be effective in preventing type 2 diabetes and associated cardiovascular events.

Back to news